Unum Therapeutics Inc. (NASDAQ:UMRX) went up by 0.40% from its latest closing price when compared to the 1-year high value of $3.72 and move down -48.8%, while UMRX stocks collected -10.07% of loss with the last five trading sessions. Press Release reported on 08/31/20 that Thinking about buying stock in Unum Therapeutics, Omeros Corp, Workhorse Group, Norwegian Cruise Line, or Delta Air Lines?
Unum Therapeutics Inc. (NASDAQ:UMRX) Worth an Investment?
Unum Therapeutics Inc. (NASDAQ:UMRX) 1 of the analysts out of 1 who provided ratings for Unum Therapeutics Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $6.00 which is -$2.5 below current price. UMRX currently has a short float of 2.75% and public float of 27.15M with average trading volume of 2.77M shares.
UMRX Market Performance
UMRX stocks went down by -10.07% for the week, with the monthly drop of -11.97% and a quarterly performance of 331.78%, while its annual performance rate touched 47.93%. The simple moving average for the period of the last 20 days is -8.29% for UMRX stocks with the simple moving average of 138.45% for the last 200 days.
Analysts’ Opinion on Unum Therapeutics Inc. (NASDAQ:UMRX)
Many brokerage firms have already submitted their reports for UMRX stocks, with Wedbush repeating the rating for UMRX shares by setting it to “Neutral”. The predicted price for UMRX socks in the upcoming period according to Wedbush is $6 based on the research report published on March 4, 2020.
Morgan Stanley, on the other hand, stated in their research note that they expect to see UMRX stock at the price of $6. The rating they have provided for UMRX stocks is “Equal-Weight” according to the report published on March 3, 2020.
H.C. Wainwright gave “Buy” rating to UMRX stocks, setting the target price at $18 in the report published on December 20, 2018.
UMRX Stocks 4.50% Far from 50 Day Moving Average
After a stumble in the market that brought UMRX to its low price for the period of the last 52 weeks, Unum Therapeutics Inc. was unable to take a rebound, for now settling with -32.80% of loss for the given period.
The stock volatility was left at 10.80%, however, within the period of a single month, the volatility rate increased by 12.90%, while the shares sank at the distance of -9.09% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +391.93% upper at the present time.
In the course of the last 5 trading sessions, UMRX went down by -10.07%, which changed the moving average for the period of 200 days to the total of +214.47% of gains for the stock in comparison to the 20-day moving average settled at $2.71. In addition, Unum Therapeutics Inc. saw 247.13% in overturn over the period of a single year with a tendency to cut further gains.
UMRX Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Unum Therapeutics Inc. (UMRX), starting from Venrock Healthcare Capital Par, who bought 101,000 shares at the price of $2.62 back on Aug 18. After this action, Rushing now owns 4,355,273 shares of Unum Therapeutics Inc., valued at $264,620 with the latest closing price.
Venrock Healthcare Capital Par, the 10% Owner of Unum Therapeutics Inc., bought 250,000 shares at the value of $2.57 during a trade that took place back on Aug 17, which means that Venrock Healthcare Capital Par is holding 4,254,273 shares at the value of $642,500 based on the most recent closing price.
UMRX Stock Fundamentals
The current profitability levels are settled at -143.02 for the present operating margin. The net margin for Unum Therapeutics Inc. stands at -141.49. Total capital return value is set at -65.65, while invested capital returns managed to touch -66.04. Equity return holds the value -87.80%, with -52.10% for asset returns.
Based on Unum Therapeutics Inc. (UMRX), the company’s capital structure generated 18.99 points for debt to equity in total, while total debt to capital is set at the value of 15.96.
The value for Enterprise to Sales is -0.42 with debt to enterprise value settled at -0.64. The receivables turnover for Unum Therapeutics Inc. is 12.27 with the total asset turnover at the value of 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.06.